# Romania Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Romania HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Romania (ROU)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $1.3B
- Products: 33
- Buyer markets: 25
- Average CAGR: +47.6%
- Global sector size: $684.5B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $301.9B | $1.2B | $112.6B | +36.0% | 20 | +0.3% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $152.2B | $23.5M | $63.4B | +218.2% | 15 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.8B | $4.0M | $16.1B | +26.5% | 7 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $12.1B | $34.3K | $16.0B | +6.0% | 3 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $29.3B | $192.0K | $15.9B | +32.1% | 6 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $23.0B | $23.8M | $13.9B | +22.3% | 7 | +0.1% |
| HS 300220 - Vaccines: for human medicine | $13.3B | $9.0M | $13.1B | +20.7% | 4 | +0.1% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $5.3M | $11.7B | -22.5% | 2 | +0.1% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $1.2M | $10.7B | +50.0% | 3 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $385.6K | $8.5B | -3.5% | 3 | +0.0% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $22.2 | $6.7B | -37.4% | 1 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $7.6B | $74.8K | $6.6B | +0.9% | 3 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $1.8M | $6.3B | +23.4% | 3 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $7.8B | $19.5K | $6.3B | +0.8% | 2 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $309.8K | $5.9B | +11.2% | 2 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $4.4B | $89.7 | $4.9B | -13.8% | 1 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $13.2K | $4.8B | -20.0% | 1 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $2.8B | $12.7K | $4.6B | +11.7% | 2 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $1.7M | $4.1B | +30.3% | 2 | +0.1% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $4.6B | $2.0K | $2.9B | +16.2% | 2 | +0.0% |
| HS 282520 - Lithium oxide and hydroxide | $1.6B | $7.1K | $2.7B | -13.3% | 1 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $46.2K | $2.1B | +4.2% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.5B | $123.6K | $2.1B | +29.8% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $3.0B | $28.4 | $2.0B | +0.4% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $6.5M | $2.0B | +12.7% | 1 | +0.2% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $2.2K | $2.0B | -6.3% | 1 | +0.0% |
| HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $8.0 | $1.9B | -22.4% | 1 | +0.0% |
| HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $4.9B | $0.1 | $1.7B | -68.1% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $22.4 | $1.4B | -10.3% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $293.2 | $1.4B | +4.6% | 1 | +0.0% |
| HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $362.3K | $1.2B | +92.2% | 1 | +0.1% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $997.5 | $1.1B | -28.7% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $677.1 | $1.1B | -1.0% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $86.5B calculated opportunity across 14 products.
- Germany (DEU): $39.0B calculated opportunity across 12 products.
- Switzerland, Liechtenstein (CHE): $35.7B calculated opportunity across 4 products.
- Belgium (BEL): $27.1B calculated opportunity across 5 products.
- Italy (ITA): $23.8B calculated opportunity across 4 products.
- Netherlands (NLD): $20.7B calculated opportunity across 6 products.
- Slovenia (SVN): $17.1B calculated opportunity across 4 products.
- China (CHN): $14.6B calculated opportunity across 5 products.
- United Kingdom (GBR): $12.3B calculated opportunity across 6 products.
- Canada (CAN): $11.7B calculated opportunity across 6 products.
- Spain (ESP): $11.6B calculated opportunity across 6 products.
- Mexico (MEX): $10.2B calculated opportunity across 5 products.

## Growth stars

- HS 300215: +218.2% average CAGR, $63.4B calculated opportunity.
- HS 293339: +92.2% average CAGR, $1.2B calculated opportunity.
- HS 330210: +50.0% average CAGR, $10.7B calculated opportunity.
- HS 300490: +36.0% average CAGR, $112.6B calculated opportunity.
- HS 300212: +32.1% average CAGR, $15.9B calculated opportunity.
- HS 330300: +30.3% average CAGR, $4.1B calculated opportunity.
- HS 290919: +29.8% average CAGR, $2.1B calculated opportunity.
- HS 382499: +26.5% average CAGR, $16.1B calculated opportunity.
- HS 382200: +23.4% average CAGR, $6.3B calculated opportunity.
- HS 300439: +22.3% average CAGR, $13.9B calculated opportunity.

## Diversification opportunities

- HS 300490: 20 buyer markets, $112.6B calculated opportunity.
- HS 300215: 15 buyer markets, $63.4B calculated opportunity.
- HS 382499: 7 buyer markets, $16.1B calculated opportunity.
- HS 300439: 7 buyer markets, $13.9B calculated opportunity.
- HS 300212: 6 buyer markets, $15.9B calculated opportunity.
- HS 300220: 4 buyer markets, $13.1B calculated opportunity.
- HS 293719: 3 buyer markets, $16.0B calculated opportunity.
- HS 330210: 3 buyer markets, $10.7B calculated opportunity.
- HS 293499: 3 buyer markets, $8.5B calculated opportunity.
- HS 382600: 3 buyer markets, $6.6B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.